Medline Inc. (MDLN) Stock Price & Analysis
Medline Inc. (MDLN) rose 6.54% to USD 36.01 as of June 10, 2026 at 00:42 UTC, according to Nexqual real-time market data.
MDLN last closed at USD 33.8; the session ranged USD 33.65–36.08 on volume of 10,143,470 shares. Market capitalization is $64.16B, with a 52-week range of USD 32.82–50.88 (NMS). Source: Nexqual, June 10, 2026 at 00:42 UTC.
Key Statistics (as of June 10, 2026 at 00:42 UTC)
| Price | USD 36.01 |
|---|---|
| Change | ▲ 6.54% (up) |
| Previous Close | USD 33.8 |
| Open | USD 33.72 |
| Day Range | USD 33.65 – 36.08 |
| 52-Week Range | USD 32.82 – 50.88 |
| Volume | 10,143,470 shares |
| Market Cap | $64.16B |
| Exchange | NMS |
Technical Analysis (MDLN)
Nexqual's technical model rates MDLN "STRONG SELL" based on 0 bullish and 5 bearish signals across 119 daily candles, as of June 10, 2026 at 00:42 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.18 (neutral) |
| vs SMA50 | Below (USD 41.33) |
| MACD | -1.97 (negative) |
Analyst Ratings (MDLN)
Wall Street analysts rate MDLN "Buy" based on 27 analysts, with a mean price target of USD 51.15 (range USD 40–62), per Nexqual as of June 10, 2026 at 00:42 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 51.15 |
| High Target | USD 62 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 24 / 4 / 0 |
Earnings (MDLN)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.32 |
| Revenue Estimate | $7.52B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.33 vs est 0.29 ▲ beat |
| 2025-12-31 | USD 0.38 vs est 0.24 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financials & Fundamentals (MDLN)
| Total Revenue | $29.14B |
|---|---|
| Revenue Growth (YoY) | +10.70% |
| Gross Margin | +25.86% |
| Operating Margin | +5.43% |
| Profit Margin | +3.32% |
| ROE | +6.05% |
| Debt / Equity | 65.31 |
| Current Ratio | 4.41 |
| Total Cash | $2.27B |
| Total Debt | $12.64B |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financial Health Score (MDLN)
Nexqual rates Medline Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:42 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 26%, operating 5% |
| Balance Sheet | Strong — $2.27B cash vs $12.6B debt |
| Cash Flow | Solid — Operating cash flow $1.47B |
| Efficiency | Mixed — ROE 6% |
Ownership (MDLN)
| Insider Ownership | +0.21% |
|---|---|
| Institutional Ownership | +99.04% |
| Shares Outstanding | 845.61M |
| Float | 357.07M |
| Short % of Float | +5.72% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Leadership (MDLN)
Medline Inc. is led by James M. Boyle (age 53), CEO & Director, per Nexqual as of June 10, 2026 at 00:42 UTC.
| CEO & Director | James M. Boyle (age 53) |
|---|---|
| Chief Financial Officer | Michael B. Drazin (age 50) |
| Chief Operating Officer | Stephen L. Miller (age 54) |
| Vice President of Corporate Communications | Ben Fox |
| Chief Marketing Officer | Jenny Lee |
Major Backers & Investors (MDLN)
Notable institutional backers of Medline Inc. include Carlyle Group Inc., H&f Corporate Investors X, Ltd., FMR, LLC, according to Nexqual as of June 10, 2026 at 00:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Carlyle Group Inc. | 22.12% |
| H&f Corporate Investors X, Ltd. | 10.23% |
| FMR, LLC | 4.32% |
| Capital Group | 2.74% |
| Invesco | 2.48% |
| Fidelity | 2.3% |
| Morgan Stanley | 1.86% |
| Lone Pine Capital | 1.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.33% |
| BlackRock | 2% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
From Medline Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Supply Chain Solutions As of December 31, 2025, we offer approximately 145,000 med-surg products from over 1,300 third-party suppliers, including nearly all leading national brands, through our Supply Chain Solutions segment.
- The U.S. governmental and regulatory authorities that enforce such laws and rules, and that issue guidance on compliance with such laws and rules include, without limitation, the FDA, the Centers for Medicare & Medicaid Services ("CMS"), other divisions of the U.S.
- In addition, the FDA and other governmental and regulatory authorities, both in and outside the United States (including the FTC, the HHS Office of the Inspector General, the DOJ, and various state Attorneys General), monitor the promotion and advertising of our products.
- The NDA Approval Process For any new drug products regulated under the Federal Food, Drug, and Cosmetic Act such as our ReadyPrep CHG cloth, a sponsor must submit a New Drug Application ("NDA"), to the FDA for review and approval.
Partnerships
- Through continual improvement of internal processes, an awareness of market and candidate driven trends, and in partnership with vendors and other outside organizations, our talent acquisition programs focus on efficient hiring processes, market awareness, and building a diverse pipeline of candidates.
- Violations are subject to civil monetary penalties of up to $124,732 (which is adjusted annually for inflation) for each violation, plus up to three times the remuneration involved, and may result in criminal fines and imprisonment of up to ten years, and/or exclusion from Medicare, Medicaid, or other governmental programs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HNGE | Hinge Health, Inc. | USD 62.78 | ▼ 1.32% |
| GEMI | Gemini Space Station, Inc. | USD 4.46 | ▲ 6.57% |
| FIGR | Figure Technology Solutions, In | USD 28.28 | ▼ 0.74% |
| STUB | StubHub Holdings, Inc. | USD 10.39 | ▲ 11.84% |
| KLAR | Klarna Group plc | USD 16.5 | ▲ 0.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:42 UTC. This page is informational and not investment advice.